Youth opioid addiction medication use rose slightly in Medicaid study, but few continued

Seeing a clinician, receiving medication and staying on it are different steps. A study of nearly 230,000 diagnosed young people found gaps across those stages.

Seeing a clinician, receiving medication and staying on it are different steps. A study of nearly 230,000 diagnosed young people found gaps across those stages.
More young people diagnosed with opioid use disorder started receiving medication during 2016–2023, but the increase was small, according to STAT’s October 2 report on a Medicaid study. Six-month continuation was already low and may have decreased. The distinction matters: starting treatment does not mean a patient receives medication or stays on it.
Scott Hadland’s study, published in JAMA Network Open, examined Medicaid enrollment and insurance claims for nearly 230,000 people ages 13–25 diagnosed with opioid use disorder, or opioid addiction. Its findings describe that diagnosed Medicaid population, not all young people in the United States.
The study followed several distinct measures of care. The first two figures below concern the full diagnosed population; the medication figures concern young people engaged in care. The one-in-32 figure is not the share of medication recipients who continued treatment.
| Measure | Population used as the denominator | Reported share |
|---|---|---|
| Started treatment by seeing a clinician | All nearly 230,000 diagnosed patients | About half |
| Had at least two appointments in the first month | All nearly 230,000 diagnosed patients | About one-third |
| Received medication | Young people engaged in care | About one in six |
| Continued medication for six months | Young people engaged in care | About one in 32 |
The exact size of the changes over time is not clear, nor are the full details of how researchers defined engagement and measured medication continuation. STAT’s October 5 follow-up said experts were unsure why six-month continuation had fallen; the longer October 2 report described that decline as possible rather than certain.
The findings come a decade after the American Academy of Pediatrics urged doctors in 2016 to offer opioid use disorder medications to adolescent and young adult patients who needed them. STAT describes buprenorphine and methadone as highly effective treatments and reports that existing research and clinical experience link longer treatment with better outcomes.
For patients under 18, access can be particularly difficult. STAT reports that federal law requires minors to have two documented unsuccessful recovery attempts without medication before starting methadone. Many specialized methadone clinics will not accept minors even after those attempts.
Fewer than 10 minors in the study received methadone across the entire period. Researchers withheld the exact count to protect privacy. Buprenorphine is easier for doctors to prescribe, but STAT cited recent research finding that few residential treatment facilities for adolescents offer it.
These restrictions describe obstacles to receiving treatment. They do not establish why six-month continuation may have declined. Some experts pointed to access difficulties for minors as a possible explanation, according to STAT’s October 5 summary.
The study also found that Black young people and other racial minority groups were more likely than white peers to drop out across the stages of care, STAT reported. The finding identifies a disparity; it does not establish the reasons for it.
Families also face unanswered treatment questions. Although many studies support these medicines’ safety and effectiveness, relatively few focus specifically on young people. Doctors therefore lack definitive answers about how long a child may need treatment or its long-term effects. Child and adolescent psychiatrist Sivabalaji Kaliamurthy told STAT that young patients can resist an open-ended commitment and families can feel apprehensive about it.
Sarah Bagley, an internist and pediatrician at Boston Medical Center who treats adolescents with addiction, emphasized care that feels safe, compassionate and nonjudgmental. She also said young people need attention as a distinct group because school and parents organize their lives differently from adults’ lives.
Addiction doctors interviewed by STAT called for primary care physicians and pediatricians with longstanding family relationships to become comfortable prescribing buprenorphine. Their proposed path is to make medication available through familiar clinicians while building care that young patients will continue to use.

Lab experiments link iron-ion exposure to DNA damage in nearby cells. Mouse tumors and astronaut molecular changes offer different kinds of evidence.
3 min

Radio observations and evidence placing the object inside our galaxy distinguish it from earlier candidates. A proposed link to nearby ultrahigh-energy particles remains unconfirmed.
3 min

Panel exports suggest a gap in capacity statistics, but warehouse stocks may inflate the estimate. Utility control over grid connections presents a separate barrier.
3 min